Acanthosis nigricans (AN) is a common dermatological condition characterized by symmetrical, dark, hyperpigmented, hyperkeratotic, velvety plaques that develop predominantly within intertriginous skin folds—most notably the posterior and lateral neck, axillae, groin, and popliteal or antecubital fossae.
Despite its distinct cutaneous appearance, acanthosis nigricans is rarely a primary skin disorder. In the vast majority of patients, it represents a visible, cutaneous sign of underlying systemic hyperinsulinemia and insulin resistance (StatPearls NBK507839). Because it frequently manifests in individuals with obesity, prediabetes, type 2 diabetes mellitus, polycystic ovary syndrome (PCOS), or metabolic syndrome, recognizing the condition is essential for initiating timely endocrine evaluation.
Many patients attempt to cleanse, scrub, or apply aggressive over-the-counter bleaching agents to affected skin under the mistaken belief that the discoloration reflects poor hygiene or superficial dirt. This approach inevitably fails and frequently induces post-inflammatory hyperpigmentation (PIH), particularly in patients with darker skin phototypes (Fitzpatrick IV–VI). Achieving meaningful clinical clearance requires a dual-track strategy: resolving the systemic hyperinsulinemic driver through targeted metabolic management (lifestyle intervention, insulin sensitizers, weight loss, or GLP-1 receptor agonist therapy) while applying evidence-based topical or procedural therapies to lighten hyperkeratotic plaques.
Direct Answer: What Causes Acanthosis Nigricans and How Is It Treated?
If you have developed thick, dark, velvety patches in your skin folds that do not lighten with washing, understanding the underlying cause and treatment ladder is critical:
- Primary Cause (Insulin Resistance): Elevated circulating insulin levels cross-react with insulin-like growth factor 1 (IGF-1) receptors on dermal fibroblasts and epidermal keratinocytes. This drives tissue proliferation, epidermal hyperkeratosis, and increased localized melanin accumulation.
- Regulatory & Treatment Reality: No drug is currently FDA-approved specifically for acanthosis nigricans itself, nor is any medication FDA-approved specifically for "insulin resistance" as a standalone indication (StatPearls NBK507839). Treatment targets the underlying medical condition driving high insulin levels.
- The Core Reversal Path (Metabolic Control): Substantial weight reduction, dietary modification, physical exercise, and insulin-sensitizing medications (such as metformin) reduce serum insulin and systematically fade skin plaques over months. Glucagon-like peptide-1 (GLP-1) receptor agonists (e.g., semaglutide, tirzepatide) that drive major weight loss and glycemic control frequently lead to marked improvement or complete resolution of metabolic AN.
- Cosmetic & Procedural Lightening (Secondary Adjuncts):
- Topical Retinoids (Tretinoin): A 2025 systematic review of randomized controlled trials (RCTs) identified topical tretinoin as the most effective single topical agent for reducing hyperpigmentation and smoothing texture in AN, particularly on the neck.
- Chemical Peels: In head-to-head clinical trials, a 15% trichloroacetic acid (TCA) peel demonstrated superior clearance of neck AN compared to a 35% glycolic acid peel at 8 weeks.
- Keratolytics: Topical formulations containing 20% urea, 12% ammonium lactate, or 2% salicylic acid accelerate stratum corneum shedding to reduce plaque thickness.
- Lasers: Long-pulsed alexandrite (755 nm) or Nd:YAG (1064 nm) lasers can reduce hyperkeratosis and hair follicle density in thick intertriginous plaques, provided low fluences are selected to protect darker skin.
- Urgent Safety Red Flag: While benign metabolic AN develops slowly over years, the sudden, rapid onset of widespread, extensive acanthosis nigricans—especially when accompanied by thick, velvety changes on the palms ("tripe palms") or mucosal membranes—can signal an underlying internal malignancy, most commonly gastric adenocarcinoma. Sudden-onset AN warrants immediate oncological and gastroenterological evaluation.
Pathophysiology: How High Insulin Transforms the Epidermis
To understand why topical skin-lightening creams alone fail, one must examine the cellular pathway connecting metabolic signaling to epidermal change.
Under normal physiological conditions, insulin binds to its specific insulin receptor (INSR) to regulate glucose transport into muscle and adipose tissue. In states of peripheral insulin resistance, higher pancreatic beta-cell insulin secretion is required to maintain euglycemia.
At high serum concentrations, circulating insulin spills over and binds with high affinity to IGF-1 receptors (IGF-1R) located on cutaneous cells:
- Keratinocytes: Stimulation of IGF-1R activates the MAPK/ERK signaling cascade, accelerating keratinocyte mitosis and promoting marked thickening of the stratum spinosum (acanthosis).
- Dermal Fibroblasts: Receptor activation causes proliferation of dermal connective tissue, leading to microscopic upfolding of dermal papillae into the overlying epidermis (papillomatosis).
The characteristic velvety texture and darkened color of acanthosis nigricans result directly from this structural architecture. The undulation of hyperkeratotic skin folds traps light, dead corneocytes, and normal cutaneous melanin, creating the visual illusion of intense pigmentation. While melanocytes may show mild secondary activity, AN is fundamentally a disorder of epidermal hyperproliferation rather than primary melanocytic overproduction.
Clinical Classification and Etiology
Acanthosis nigricans is categorized into distinct clinical variants based on the underlying causative driver:
| Variant | Primary Cause / Etiology | Typical Clinical Presentation | Course & Prognosis |
|---|---|---|---|
| Obesity-Associated (Benign AN) | Visceral adiposity, hyperinsulinemia, metabolic syndrome | Gradual onset; neck, axillae, groin; symmetric | Reversible with weight loss and insulin reduction |
| Syndromic AN (e.g., PCOS, HAIR-AN) | Polycystic ovary syndrome, severe insulin resistance, hyperandrogenism | Neck, axillae, inframammary folds; accompanied by hirsutism & acne | Responds to combined OCPs, metformin, and weight loss |
| Drug-Induced AN | Systemic corticosteroids, high-dose niacin, OCPs, growth hormone | Variable distribution following medication initiation | Clears gradually upon discontinuation of trigger drug |
| Hereditary / Acral AN | Autosomal dominant FGFR3 gene mutations without metabolic disease | Present in childhood; prominent on knees, elbows, knuckles | Persistent; cosmetic topicals provide mild improvement |
| Malignant AN | Paraneoplastic secretion of TGF-alpha by internal adenocarcinoma | Sudden, rapid onset; severe; palms (tripe palms), lips, mucosa | Paraneoplastic warning; tracks underlying tumor course |
Metabolic and Endocrine Drivers
The vast majority of outpatient presentation represents obesity-associated or syndromic AN. In adult and pediatric patients with elevated body mass index (BMI), hyperinsulinemia is the predominant driver. Primary care management guidelines outlined in medical reviews (PMC9678372) emphasize that identifying AN in adolescents serves as an early window for preventing metabolic disease.
In women, AN is a hallmark cutaneous feature of HAIR-AN syndrome (Hyperandrogenism, Insulin Resistance, and Acanthosis Nigricans), an extreme subtype of PCOS. High circulating insulin acts synergistically with luteinizing hormone (LH) on ovarian theca cells to stimulate excess androgen synthesis. This creates a dual presentation: metabolic skin plaques (AN) co-occurring with androgenic cutaneous signs (facial hirsutism and recalcitrant acne). Management requires combined oral contraceptives containing antiandrogenic progestins alongside metformin to address both reproductive and metabolic signaling.
Thiazolidinediones and Insulin Sensitizer Mechanisms
Beyond metformin, second-line insulin sensitizers such as thiazolidinediones (rosiglitazone, pioglitazone) act as synthetic ligands for peroxisome proliferator-activated receptor-gamma (PPAR-gamma). By enhancing insulin sensitivity in peripheral adipose and muscle tissues, thiazolidinediones lower basal pancreatic insulin output, removing the chronic IGF-1 receptor stimulus on epidermal keratinocytes. Clinical trials demonstrate that improving peripheral glucose uptake reduces both cutaneous hyperkeratosis and systemic metabolic markers.
Pediatric Screening Guidelines
The American Diabetes Association (ADA) recognizes acanthosis nigricans as a pivotal physical indicator for pediatric diabetes risk. ADA guidelines (StatPearls NBK431046) recommend initiating routine type 2 diabetes screening (fasting plasma glucose, HbA1c, or oral glucose tolerance testing) in children and adolescents who are overweight (BMI > 85th percentile for age and sex) or obese (BMI > 95th percentile) starting at age 10 (or at onset of puberty) if they exhibit acanthosis nigricans or other signs of insulin resistance.
Malignant Acanthosis Nigricans Red Flags
Malignant AN is a rare paraneoplastic syndrome caused by tumor-derived growth factors—most notably transforming growth factor-alpha (TGF-alpha)—circulating in blood and overstimulating epidermal EGF/IGF-1 receptors. Key clinical features distinguishing malignant AN from benign metabolic AN include:
- Rapid Onset & Extensive Spread: Sudden appearance and aggressive progression over weeks to months in a non-obese individual.
- Atypical Anatomic Sites: Involvement of non-flexural areas, including the oral mucosa (papillomatous swelling of lips and tongue), eyelids, umbilical region, and dorsal hands.
- Tripe Palms (Acanthosis Palmaris): Thickened, velvety, honeycomb-like ridges on the palmar surfaces of the hands, occurring in over 90% of malignant AN cases.
- Associated Malignancies: Over 60% of malignant AN cases stem from gastric adenocarcinoma, followed by pancreatic, ovarian, lung, and colorectal carcinomas.
Evidence-Based Treatment Ladder
Because no medication is FDA-approved specifically for acanthosis nigricans, therapy follows an evidence-based ladder combining systemic cause management with targeted topical and procedural modalities.
Step 1 & Step 2: Systemic Metabolic Management
Addressing the hyperinsulinemic root cause is the only mechanism capable of producing permanent clearance of metabolic AN.
- Lifestyle & Dietary Intervention: A 5% to 10% reduction in total body weight significantly improves peripheral insulin sensitivity, reducing basal insulin secretion. As serum insulin levels decline toward normal ranges, keratinocyte IGF-1R overstimulation ceases, allowing the stratum corneum to normalize over 3 to 12 months.
- GLP-1 Receptor Agonists: High-potency GLP-1 and dual GLP-1/GIP receptor agonists (e.g., semaglutide, tirzepatide) have transformed the clinical management of metabolic AN. By inducing substantial weight loss (15% to 22% of total body weight in clinical trials) and restoring glycemic control, these agents eliminate the hyperinsulinemic driver. Patients who experience skin changes alongside body weight changes should note that the same GLP-1-driven weight loss behind Ozempic face also serves as the primary engine for reversing intertriginous acanthosis nigricans. Furthermore, understanding how GLP-1 weight loss reshapes both body contour and metabolic skin conditions like AN helps set realistic expectations for skin tightening versus textural improvement.
- Metformin: As an oral biguanide, metformin suppresses hepatic gluconeogenesis and enhances peripheral insulin sensitivity without inducing hypoglycemia. Clinical trials evaluating pediatric and adult AN show that metformin significantly reduces plaque neck thickness and pigmentation over 24 weeks, particularly when combined with dietary modification.
- Oral Retinoid Escalation (Severe Cases): In severe, widespread, or syndromic AN cases where topical agents prove ineffective, clinical case series (Walling 2003, Romo 2008) demonstrate that systemic oral retinoids (isotretinoin, acitretin) under strict medical supervision can induce marked clearing of hyperkeratotic plaques by disrupting epidermal differentiation. Systemic retinoids require close monitoring for mucocutaneous toxicity, hypertriglyceridemia, and teratogenic precautions, and plaques frequently recur after drug discontinuation.
- Access & Cost Considerations: While metformin is widely available as a low-cost generic ($4 to $20 per month), brand-name GLP-1 therapies carry substantial financial requirements, often exceeding $900 to $1,300 per month out of pocket when prescribed off-label for weight management without type 2 diabetes. Reviewing GLP-1 access and cost considerations is valuable for patients planning long-term therapy.
Step 3: Topical Actives (Retinoids and Keratolytics)
Topical agents provide localized cosmetic improvement by normalizing keratinocyte differentiation and loosening intercorneocyte desmosomal bonds.
- Topical Tretinoin (0.05%–0.1% Cream): Retinoic acid binds to nuclear retinoic acid receptors (RARs), downregulating hyperkeratosis and accelerating epidermal turnover. In a 2025 systematic review of topical RCTs published in Frontiers in Medicine (DOI 10.3389/fmed.2025.1641322, synthesizing 7 RCTs and 268 patients), topical tretinoin emerged as the most effective single topical intervention for fading AN pigmentation on the neck. Patients considering prescription tretinoin can read how tretinoin compares with over-the-counter retinol to understand potency differences and barrier adaptation protocols.
- Topical Keratolytics: High-concentration urea (20% to 40%), ammonium lactate (12%), and salicylic acid (2% to 6%) disrupt intercellular keratin protein bonds, facilitating the sloughing of thickened stratum corneum plaques. The clinical rationale mirrors the same keratolytic-plus-retinoid logic used for keratosis pilaris, where mechanical softening must precede retinoid renewal.
Step 4: In-Office Chemical Peels and Energy-Based Devices
When topical regimens produce incomplete clearance, structured in-office procedures accelerate textural smoothing.
- Trichloroacetic Acid (TCA) Peels: Trichloroacetic acid induces protein denaturation and epidermal chemo-exfoliation. The 2025 systematic review of topical RCTs evaluated chemical peel protocols and established that a 15% TCA peel achieved significantly superior clinical clearance of neck acanthosis nigricans compared to a 35% glycolic acid peel at 8 weeks, with lower rates of post-peel irritation.
- Laser Interventions: Long-pulsed alexandrite (755 nm) and 1064-nm Nd:YAG lasers have been successfully employed off-label to treat thick, hair-bearing AN plaques in the axillae and neck. Laser energy targets follicular melanin, reducing coarse hair shafts and thinning hyperkeratotic epidermal ridges. Because AN disproportionately affects darker skin phototypes, reviewing the alexandrite and Nd:YAG lasers evaluated for skin of color safety is essential before initiating light-based therapy.
Comparative Evidence Matrix: Topical and Procedural Therapies
The following table synthesizes clinical trial parameters, mechanism of action, efficacy timelines, and safety profiles across evidence-based AN interventions based on primary literature:
| Treatment Modality | Mechanism of Action | Evidence Base & Sample Size | Onset / Timeline | Key Limitations & Safety Notes |
|---|---|---|---|---|
| Lifestyle & Weight Loss | Reduces serum insulin; eliminates IGF-1R overstimulation | Multi-center metabolic trials; gold standard | 3 to 12 months | Requires sustained behavior change; zero procedural cost |
| Metformin | Suppresses hepatic gluconeogenesis; improves sensitivity | Randomized clinical trials (Walling 2003, Romo 2008) | 12 to 24 weeks | GI side effects (nausea, diarrhea); off-label for AN |
| GLP-1 Receptor Agonists | Potent weight reduction & systemic glycemic control | Large STEP/SURPASS trials; observational AN data | 8 to 24 weeks | High out-of-pocket cost ($1,000+/mo); GI side effects |
| Tretinoin 0.05% Cream | Normalizes keratinocyte mitosis; thins stratum corneum | 2025 Systematic Review (7 RCTs, N=268) | 4 to 12 weeks | Local erythema, peeling, irritation; requires sun protection |
| 15% TCA Chemical Peel | Protein coagulation; rapid stratum corneum exfoliation | Head-to-head RCT vs 35% glycolic acid (2025 review) | 4 to 8 weeks | Risk of PIH in dark skin if unbuffered; requires serial sessions |
| Urea 20% / Ammonium Lactate | Solubilizes intercellular matrix; hydrates corneocytes | Clinical case series & comparative trials | 6 to 12 weeks | Stinging on broken skin; requires ongoing application |
| Oral Isotretinoin | Systemic keratinocyte differentiation modulation | Case series (severe/syndromic cases) | 8 to 16 weeks | Severe teratogenicity, cheilitis, hyperlipidemia; high relapse |
| Nd:YAG 1064 nm Laser | Targets deep follicle melanin; thins papillary ridges | Small interventional trial series | 8 to 16 weeks | High session cost; risk of thermal injury if fluences excessive |
Chemical Peel Protocol Comparison for Intertriginous AN
Chemical peeling in flexural, intertriginous skin requires strict protocol adjustments to prevent severe chemical burns or post-inflammatory hyperpigmentation.
Flexural skin on the neck and axillae possesses a thinner stratum corneum and higher cutaneous occlusion compared to facial skin. Clinicians applying TCA or glycolic acid to flexural AN must use lower concentrations (10% to 15% TCA) and shorter dwell times, avoiding aggressive rubbing to prevent deep dermal penetration. Post-peel care relies on barrier repair creams (ceramides, petrolatum) and strict sun avoidance.
Skin of Color Considerations and Common Patient Errors
Acanthosis nigricans exhibits a significantly higher prevalence in populations of African, Hispanic, Native American, and South Asian heritage. This pattern reflects both a higher genetic predisposition toward peripheral insulin resistance and increased visual contrast of hyperkeratotic plaques on darker skin phototypes.
The Scrubbing Trap
The single most damaging mistake patients make when noticing dark neck plaques is applying loofahs, harsh physical scrubs, pumice stones, or concentrated bleaching creams (such as unregulated hydroquinone or caustic lemon juice concoctions).
Because AN is driven by basal keratinocyte proliferation deep within the epidermis—not superficial surface dirt—mechanical friction cannot scrub the plaque away. Instead, friction disrupts the epidermal lipid barrier and triggers an inflammatory response. In Fitzpatrick IV–VI skin, inflammatory mediators stimulate dermal melanocytes to deposit excess melanin into the papillary dermis. This overlays post-inflammatory hyperpigmentation (PIH) on top of the existing acanthosis nigricans, making the area darker and far more resistant to topical treatment.
Safe Skincare Rules for Darker Skin
- Eliminate Friction: Wash flexural skin folds gently using fingertips and mild, non-soap synthetic detergent cleansers.
- Buffer Actives: When starting tretinoin 0.05% or glycolic acid, apply a lightweight ceramide moisturizer first (the "sandwich method") to reduce localized barrier breakdown.
- Daily Sun Protection: Broad-spectrum mineral sunscreen (SPF 30+) applied to exposed neck areas prevents UV radiation from darkening existing epidermal hyperkeratosis.
Differential Diagnosis: Distinguishing AN from Look-Alikes
Correctly identifying acanthosis nigricans prevents inappropriate antifungal or anti-inflammatory treatment.
- Tinea Versicolor: Caused by Malassezia fungal overgrowth, presenting as fine scaly macules on the chest and back that clear with antifungal shampoos. Unlike AN, tinea versicolor lacks velvety skin thickening.
- Dermatitis Neglecta: Caused by inadequate washing of a localized skin area, resulting in an accumulation of sebum, keratin, and dirt. It is immediately distinguished from AN because dermatitis neglecta clears completely when wiped with an alcohol swab.
- Terra Firma-Forme Dermatosis: A benign retention hyperkeratosis presenting as dirt-like brownish plaques on the neck or ankles that resists soap and water but wipes clean with 70% isopropyl alcohol.
- Confluent and Reticulated Papillomatosis (Gougerot-Carteaud): Hyperpigmented papules coalescing into a reticulated net-like pattern on the central chest and epigastrium, highly responsive to oral minocycline.
Frequently Asked Questions
Can acanthosis nigricans go away on its own?
Acanthosis nigricans does not resolve spontaneously without addressing the underlying driver. However, when the root metabolic cause is successfully treated—such as achieving sustained weight loss, improving insulin sensitivity through diet and exercise, or discontinuing a causative medication—the elevated serum insulin levels decline. As insulin-mediated overstimulation of epidermal receptors stops, the skin folds gradually lighten and smooth out over several months.
Do skin-lightening creams or scrubbing work for a dark neck?
No. Over-the-counter skin-lightening creams and mechanical scrubbing do not work for acanthosis nigricans. AN is caused by epidermal hyperkeratosis and tissue proliferation driven by internal insulin signals, not superficial dirt or melanocyte hyperactivity. Scrubbing the area irritates the skin and triggers post-inflammatory hyperpigmentation (PIH), making the discoloration worse, particularly in skin of color.
Will losing weight or taking a GLP-1 medication like Ozempic clear it?
Significant weight loss induced by lifestyle changes, bariatric surgery, or GLP-1 receptor agonist medications (e.g., semaglutide, tirzepatide) is one of the most effective ways to reverse metabolic acanthosis nigricans. By reducing visceral fat and restoring insulin sensitivity, these treatments lower circulating insulin levels, allowing skin thickness and pigmentation to return toward normal over 3 to 12 months.
How quickly can metformin clear dark neck plaques?
Metformin does not produce immediate overnight clearing because it acts indirectly by improving insulin sensitivity. In clinical trials evaluating pediatric and adult acanthosis nigricans, noticeable flattening of hyperkeratotic neck plaques and lightening of pigmentation typically require 12 to 24 weeks of continuous metformin therapy combined with dietary modification.
Does laser hair removal help acanthosis nigricans in the armpits?
Yes, in selected cases. When acanthosis nigricans occurs in hair-bearing axillary or groin folds, long-pulsed 1064-nm Nd:YAG or alexandrite laser treatments can reduce both thick hair shafts and superficial hyperkeratosis. By thinning the follicular density and thermalizing dermal papillae, laser therapy smooths the velvety surface texture, making topical retinoids and keratolytics easier to apply.
Sources
- StatPearls — Insulin Resistance (NBK507839), ncbi.nlm.nih.gov/books/NBK507839/
- StatPearls — Pediatric Type 2 Diabetes (NBK431046), ncbi.nlm.nih.gov/books/NBK431046/
- Acanthosis nigricans in the pediatric population: a narrative review of the current approach to management in primary care, PMC, pmc.ncbi.nlm.nih.gov/articles/PMC9678372/
- The efficacy of topical treatments for acanthosis nigricans: a systematic review of randomized controlled trials, Frontiers in Medicine (2025), DOI: 10.3389/fmed.2025.1641322
- DermNet — Acanthosis nigricans, dermnetnz.org/topics/acanthosis-nigricans
- Cleveland Clinic — Acanthosis Nigricans, my.clevelandclinic.org/health/diseases/12168-acanthosis-nigricans
- Medscape — Acanthosis Nigricans Treatment & Management, emedicine.medscape.com/article/1102488-treatment
